NEW – antidepressant vortioxetine (Brintellix®)
Lundbeck have launched a new antidepressant, vortioxetine, which is licensed in the UK for the treatment of major depressive illness in adults. The mechanism of action is thought to be related to its direct modulation of serotonergic receptor activity and inhibition of the serotonin (5-HT) transporter. This leads to modulation of neurotransmission in several systems, including predominantly the serotonin but also the norepinephrine, dopamine, histamine, acetylcholine, GABA and glutamate systems. In animal studies, this multimodal activity is considered responsible for antidepressant and anxiolytic-like effects and the improvement of cognitive function, learning and memory observed with vortioxetine.
Clinical studies have shown efficacy with vortioxetine for treating patients with major depressive disorder, and studies have demonstrated improvements with cognitive symptoms. The most common side effect was nausea, which was usually transient and did not lead to treatment cessation.
Brintellix® is available in 5mg, 10mg and 20mg strengths in packs of 28 tablets, which contain vortioxetine hydrobromide.
The basic NHS price for all strengths is £27.72 per pack. Full prescribing information can be found in the Summary of Product Characteristics (SPC) which is available here:
Photo by Andrew Mason (London, UK) [CC BY 2.5 (http://creativecommons.org/licenses/by/2.5)], via Wikimedia Commons